Ten Steps to Developing a National Agenda to Address Financial Conflicts of Interest in Industry Sponsored Clinical Research

Abstract

Financial liaisons between clinical researchers, research institutions, and industrial sponsors have gained momentum in recent years. In the process, it has been argued by many that trust in the research infrastructure is being eroded by the financial conflicts of interest that emerge from these arrangements. Yet, the financial resources of industry are needed to continue technology transfer from the bench to the bedside. Policy makers and government regulators are currently struggling to determine how to best manage financial conflicts of interest that emerge from these liaisons. Various organizations and governmental entities have proposed different strategies. This paper explores the limitations of existing measures and recommends that a unified national agenda is needed. We propose 10 steps to develop an agenda to address financial conflicts of interest in industry-sponsored clinical research.

Supported by National Institutes of Health/National Library of Medicine, Project number: 1G13LM07J12-01.

Notes

Supported by National Institutes of Health/National Library of Medicine, Project number: 1G13LM07J12-01.

21 CFR 54 et seq

21 CFR pt. 54, and applicable portions of parts 312, 314, 320, 330, 601, 807, 812, 814, and 860

42 CFR Section 50.603

Bayh-Dole Act. (1980). Pub L No. 96–517

General Accounting Office (GAO). (2001). Report to the Ranking Minority Member, Subcommittee on Public Health, Committee on Health, Education, Labor, and Pensions, U.S. Senate. GAO-02-89 (November)

Hippocrates Meets Mammon. (1990). The Economist (September 22, 1999): 195